CRISPR Therapeutics (NASDAQ:CRSP) Stock Rating Upgraded by Wall Street Zen

CRISPR Therapeutics (NASDAQ:CRSP) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other research analysts also recently weighed in on the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $55.00 price target on shares of CRISPR Therapeutics in a research note on Thursday. Morgan Stanley set a $60.00 target price on shares of CRISPR Therapeutics and gave the stock an “equal weight” rating in a research report on Thursday, June 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Friday, July 17th. UBS Group set a $80.00 price target on shares of CRISPR Therapeutics in a research report on Friday, June 12th. Finally, Citizens Jmp restated a “market outperform” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $68.06.

CRISPR Therapeutics Stock Performance

CRSP stock opened at $53.52 on Friday. The company has a quick ratio of 17.85, a current ratio of 17.85 and a debt-to-equity ratio of 0.34. The firm has a market cap of $5.17 billion, a PE ratio of -11.24 and a beta of 1.74. The business has a 50 day moving average of $52.37 and a 200-day moving average of $52.30. CRISPR Therapeutics has a 12-month low of $44.12 and a 12-month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. The business had revenue of $10.18 million for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. As a group, sell-side analysts expect that CRISPR Therapeutics will post -4.53 earnings per share for the current year.

Insider Buying and Selling

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $55.62, for a total transaction of $210,577.32. Following the sale, the insider owned 19,357 shares in the company, valued at $1,076,636.34. This trade represents a 16.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Versant Capital Management Inc grew its position in shares of CRISPR Therapeutics by 175.1% in the 2nd quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock worth $25,000 after buying an additional 296 shares during the last quarter. Mcguire Capital Advisors Inc. bought a new stake in CRISPR Therapeutics in the fourth quarter valued at $25,000. Ramirez Asset Management Inc. purchased a new position in CRISPR Therapeutics during the 4th quarter valued at $26,000. Rothschild Investment LLC raised its holdings in CRISPR Therapeutics by 836.7% in the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after purchasing an additional 502 shares in the last quarter. Finally, Oakworth Capital Inc. bought a new position in CRISPR Therapeutics in the 4th quarter worth $34,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics News Roundup

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: HC Wainwright remains bullish: The firm maintained a “Buy” rating and an $80 price target, while modestly narrowing its projected losses for fiscal 2026, fiscal 2027 and fourth-quarter 2027. The revisions suggest slightly better expected profitability, although CRISPR is still forecast to remain unprofitable. HC Wainwright CRISPR Therapeutics estimates
• Positive Sentiment: Other bullish coverage supports sentiment: Piper Sandler reaffirmed its “Buy” rating on CRISPR Therapeutics, while Brookline Capital Markets raised its fiscal 2027 EPS forecast to a loss of $4.51 from a loss of $5.05. Piper Sandler reaffirms Buy rating
• Neutral Sentiment: Wells Fargo issued a Hold rating: The rating indicates a more cautious view and may limit the impact of the bullish recommendations, particularly with CRSP still reporting substantial losses. Wells Fargo Hold rating
• Negative Sentiment: Brookline lowered its fiscal 2026 outlook: The firm increased its projected fiscal 2026 loss to $5.63 per share from $5.36 and reduced its fourth-quarter 2026 forecast to a $1.87-per-share loss from $1.69. These revisions highlight near-term earnings pressure.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.